ClinicalTrials.Veeva

Menu

Magnetic Stimulation to Treat VT Storm (STAR-VT)

University of Pennsylvania logo

University of Pennsylvania

Status

Completed

Conditions

Ventricular Tachycardia

Treatments

Device: Magstim SuperRapid

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Ventricular Tachycardia storm is a medical emergency characterized by three or more episodes of ventricular arrhythmia within 24 hours and associated with a significantly increased mortality and massive health resource utilization. Several therapies are utilized including sympathetic blockade (through deep sedation and beta blockers), antiarrhythmic drugs, implantable cardioverter defibrillator (ICD) reprograming where applicable, and catheter ablation. Despite standard intervention, mortality rates remain high and additional therapeutic options are actively being investigated.

The overall objective of this proposal is to investigate whether transcutaneous magnetic stimulation designed to inhibit the left stellate ganglion can be used in this population. This is a single-center, randomized, sham-controlled trial to assess the efficacy of transcutaneous magnetic stimulation of the left stellate ganglion to treat patients with ventricular tachycardia storm.

Enrollment

26 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ≥ 3 episodes of VT in 24 hours

Exclusion criteria

  • Pregnancy
  • Implanted ventricular assist device
  • Metal implanted in head or neck (except the mouth)
  • Implanted medication pumps
  • Cochlear implant
  • Implanted brain stimulator
  • Ocular implant
  • History of active malignancy in region of stimulation (neck)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

26 participants in 2 patient groups

Control
Sham Comparator group
Description:
Patients will receive one hour of sham stimulation.
Treatment:
Device: Magstim SuperRapid
Device: Magstim SuperRapid
Active
Experimental group
Description:
Patients will receive one hour of active magnetic stimulation to the left stellate ganglion.
Treatment:
Device: Magstim SuperRapid
Device: Magstim SuperRapid

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems